The Cali Fund, set up to raise $1bn a year for biodiversity from drug companies, remains near empty Big pharmaceutical companies have been accused of “free-riding on nature”, after a landmark biodiversity fund that invites businesses to put some of their profits back into conservation was left virtually empty.

Also readBarclays cutting 5,000 jobs as it increases reliance on AI

The Cali Fund set out to raise $1bn (£750m) annually, by asking companies that profit from nature’s genetics to contribute towards conservation in low-income countries. But more than 18 months after the fund was launched, it remains far below this target. Continue reading...

Also readYou be the chancellor: play our budget game to see if you can balance the books